Progenics Pharmaceuticals, Inc. (PGNX) Reports In-Line Q1 Loss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Progenics Pharmaceuticals, Inc. (PGNX) Reports In-Line Q1 Loss

Progenics Pharmaceuticals Announces First Quarter 2014 Financial Results

May 9, 2014 7:30 AM EDT

TARRYTOWN, N.Y., May 9, 2014 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its results of operations for the quarter ended March 31.

Net loss for the quarter was $9.3 million or $0.15 diluted per share, compared to net loss of $11.3 million or $0.22 diluted per share in the 2013 period. Progenics ended the quarter with cash, cash equivalents and securities of $96.2 million, an increase of $28.1 million in the quarter resulting primarily from public offering proceeds.

First quarter revenue totaled $1.8 million, down from $2.2 million in 2013, reflecting royalty income of $0.7 million compared to $1.2 million in the 2013... More